Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story PEPFAR survives rescissions Senate Republicans are ...

OTTAWA — An Alberta Conservative MP said she thinks the measles outbreak in her province can be traced back to the COVID ...

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...

AstraZeneca PLC closed 21.60% below its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca has announced a new clinical study titled ‘Exacerbations and Their Outcomes in Egyptian Patients (EXACOS EG Population),’ which aims to explore the burden of severe exacerbations of COPD ...

Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.